Partnering for scientific leadership

The best science doesn't happen in isolation.

Our partnering approach

From pre-clinical research collaborations through to late-stage development and global commercialisation deals, our partnering strategy focuses on innovative scientific capabilities and value-enhancing business development opportunities across our main therapy areas.

Our deals are structured to drive scientific progress from the bench to the bedside and we aim to create partnerships founded on trust and transparency that achieve mutually agreed goals.

Our integrated approach combines our scientific and commercial expertise with our significant business development know-how and experience.

We are also interested in leveraging our development and commercial capabilities in targeted growth markets, which include Japan and the Emerging Markets.


  • Research collaborations

    Conducting early stage research with the best academic researchers across the globe

  • Peer collaborations

    Maximising pipeline assets and expertise of both partners to create value for patients

  • In-licensing and acquisitions

    Pursuing partnering, in-licensing and acquisitions to strengthen our main therapy area portfolios

  • Externalisation

    Creating value from the strong science in our portfolio by out-licensing technologies and potential new medicines

Our areas of focus

Across our biologics and small molecule research, we are concentrating our scientific efforts in our three main therapy areas. We also remain active in Infection and Neuroscience and are actively exploring collaborations that support our personalised healthcare strategy with biomarker and diagnostic technologies.

Respiratory, Inflammation and Autoimmunity

AstraZeneca has a long heritage in respiratory disease with 40 years of experience and a strong franchise of marketed products. Our portfolio includes a range of differentiated inhaled and targeted therapies, such as biologics, novel combinations and new devices to treat the full range of asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis. We are also developing innovative treatments within inflammatory and autoimmune diseases, with a pipeline of promising assets in rheumatology, dermatology, gout, systemic lupus and rheumatoid arthritis. Our innovative precision approaches will ensure the right treatment for the right patient.

Areas of interest include:

  • Asthma
  • Chronic obstructive pulmonary disease (COPD)
  • Idiopathic pulmonary fibrosis (IPF)
  • Rheumatology focus in areas such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis and gout
  • Opportunistic interest in co-morbidities or adjacent diseases to the above with similar prescriber bases

Cardiovascular and Metabolic diseases

Our Cardiovascular and Metabolic diseases (CVMD) portfolio is focused on reducing morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular disease, diabetes and chronic kidney disease indications. We aim to provide next-generation treatments that can stop or even reverse disease progression.

AstraZeneca is uniquely equipped to address targets using a broad variety of approaches, including small molecules, antisense oligonucleotides, modified RNA, anti-micro RNA molecules, antibodies, peptides and recombinant proteins.

Areas of interest include:

  • Dyslipidaemia, atherosclerosis and chronic heart disease
  • Heart failure and cardiac regeneration
  • Chronic kidney disease and diabetic nephropathy
  • NASH (non-alcoholic steatohepatitis)
  • Diabetic islet cell health, insulin sensitisation, and the return of beta cell function

Oncology

Our broad pipeline focuses on four disease areas – breast, ovarian, lung and haematological cancers. These are being targeted through four key platforms – immunotherapy, the genetic drivers of cancer and resistance, DNA damage repair and antibody-drug conjugates. We have one of the most exciting and comprehensive immuno-oncology portfolios in the industry. In particular, we are uniquely positioned to explore synergistic combinations of immunotherapies, both with each other and with our own highly targeted small molecules, supported by external collaborations.

Areas of interest include:

  • Immune-mediated therapies
  • Genetic and molecular targeting
  • DNA damage repair
  • Antibody-drug conjugates
  • Biologically synergistic combinations
  • Lung cancer, breast cancer, ovarian cancer, haematology

Infection and Vaccines

AstraZeneca aims to discover and develop effective, targeted therapies and vaccine approaches to address unmet medical needs.

Areas of interest include:

  • Serious bacterial infections
  • Respiratory viruses
  • Novel vaccines

Neuroscience

A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders. With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, we continue to push the boundaries of science in neuroscience in collaboration with others across industry and academia.

Areas of interest include:

  • Neurodegenerative disorders
  • Neurodevelopmental disorders
  • Chronic analgesia

Personalised healthcare

Personalised healthcare is at the heart of AstraZeneca’s approach to discovering and developing medicines, because we believe in the value it can deliver. This is reflected in our pipeline, with approximately 80% of our programmes benefiting from a personalised healthcare or biomarker platform. Our bold ambition is to transform patients’ lives through personalised healthcare, ensuring that innovative treatments are matched to those patients who are likely to benefit most – the right drug for the right patient at the right time. This will benefit patients, payers and healthcare systems broadly. Our personalised healthcare and biomarker team follows the science and would look to collaborate with a wide range of expert partners to identify, validate and manufacture diagnostics to regulatory standards, and for innovative biomarker capabilities.

Areas of interest include:

  • Methodology for patient selection
  • Disease identification
  • Pharmacological assessment
  • Drug response monitoring

Technology

We are interested in cutting-edge technologies to enhance the quality, effectiveness and productivity of our research and translational capabilities.

Areas of interest include:

  • Target validation tools and technologies
  • Novel high throughput screening/lead generation approaches
  • Novel chemical libraries with evidence of biological relevance
  • Predictive safety and predictive efficacy platforms
  • Drug delivery platforms and medical device technologies, in particular methods for inhaled and parenterally-administered drugs
  • Novel delivery, manufacturing and analytical processes, in particular those applicable to nucleic acid-based drugs and antibody-drug conjugates
  • New systems for drug targeting
  • Stem cell biology
  • Novel technologies for antibodies and vaccines
  • Clustered regularly interspaced short palindromic repeats (CRISPR)

The partnering lifecycle

Why partner with AstraZeneca?

Our science-driven culture, breadth of expertise and focused approach to R&D makes us a valued partner

Scientific capabilities

By combining our expertise in drug discovery and development with the best external scientific capabilities and technologies, we stimulate innovation across the entire drug life-cycle.

Stakeholder insights

Our dedicated teams ensure physician and payer considerations are embedded in our R&D decision-making from an early stage by providing informed, evidence-based perspectives on clinical and economic impact. We design studies that allow the impact and value of our molecules to be evaluated in clinical and real world settings.

A global presence

We have a commercial presence in over 100 countries, research capabilities on three continents and collaborations across both developed and emerging markets. By combining our therapy area expertise with a deep global knowledge of customers, regulators and payers, and the local knowledge and expertise of our collaboration partners, we can develop, register and commercialise medicines that best meet local patient needs.

Alliance and integration management

We are committed to creating strong, long-term partnerships that will speed the delivery of innovative new medicines to the people that need them. Experience tells us that when partnerships aren’t actively managed, the potential value to both partners is jeopardised.

Our Alliance and Integration Management team is engaged throughout the deal process, starting as early as due diligence and contract negotiations. Gaining an early understanding of the strategic, operational and cultural fit between AstraZeneca and our partners enables us to structure the partnership governance and staff the partnership to be most effective right from the start.

Based on our extensive work in a wide range of complex business and scientific collaborations, we have developed industry leading processes and tools that ensure a smooth acquisition integration or a successful alliance execution. We also actively monitor and regularly assess the performance of our partnerships, embedding the learnings in new ventures.

We believe that the most successful relationships are built on trust and transparency, and we are committed to forging strong relationships with our partners at all levels of the enterprise.

What our partners say

Get in touch

Please select a stage from the dropdown below to find the relevant contact

Early-stage

Small Molecules, Innovative Medicines and Early Development (IMED)

Business Development Leadership

Kumar Srinivasan

Vice-President, Scientific Partnering & Alliances

Respiratory, Inflammation and Autoimmunity

John Taylor

Director, Scientific Partnering & Alliances

Cardiovascular and Metabolic diseases

Kay Brickman

Director, Scientific Partnering & Alliances

Oncology

Maria Dahl

Executive Director, Scientific Partnering & Alliances

Neuroscience

Bavani Shankar

Director, Scientific Partnering & Alliances

External Collaborations (Government/University/Non-profit)

Li Wang

Director, Scientific Partnering & Alliances

Technology

Iain Comley

Director, Scientific Partnering & Alliances

Out-licensing/spin-outs

Kumar Srinivasan

Vice-President, Scientific Partnering & Alliances

Biologics, MedImmune

Business Development Leadership

Reg Seeto

Vice-President, Biotech Partnering & Strategy

Respiratory, Inflammation and Autoimmunity

Eric Paradise

Senior Director, Biotech Partnering & Strategy

Cardiovascular and Metabolic diseases

Eric Victory

Vice-President, Biotech Partnering & Strategy

Oncology

Simon Tsang

Senior Director, Biotech Partnering & Strategy

Infection

Derek Woodward

Associate Director, Biotech Partnering & Strategy

Neuroscience

Philip Oliver

Director, Biotech Partnering & Strategy

External Collaborations (Government / University / Non-profit)

Jarrod Borkat

Senior Director, Biotech Partnering & Strategy

Technology

Jung Lee

Associate Director, Biotech Partnering & Strategy

Out-licensing / Spin-outs

Mickey Kim

Director, Biotech Partnering & Strategy

Mid to late-stage & commercial

Search and Evaluation

Respiratory, Inflammation and Autoimmunity

John Cantello

Head, RIA Evaluation

Cardiovascular and Metabolic diseases

Karima Boubekeur

Head, Cardiovascular and Metabolic diseases Evaluation

Oncology

Nina Mojas

Head, Oncology Evaluation and Early Portfolio

Infection, Neuroscience & Gastrointestinal

Jonas Niaura

Director, Infection, Neuroscience & Gastrointestinal

Business Development Operations

Business Development Operations Leadership

Shaun Grady

Vice-President, Business Development Operations

Business Development Operations

Cecilia Schott

Head, Personalised Healthcare

Alliance & Integration Management

Steven Twait

Vice-President, Alliance & Integration Management

Corporate Development

Corporate Development

Mike Diem

Vice-President, Corporate Strategy

Rodolphe Grepinet

Executive Director, Corporate Strategy

Michael Gutch

Executive Director, Corporate Strategy

Tyrell Rivers

Executive Director, Corporate Strategy

John Trainer

Vice-President, Corporate Development

Yasuyuki Uechi

Vice-President, Regional Business Development, Asia Pacific